ArticleCancer cell international2026
PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAdvanced clear cell renal cell carcinoma (ccRCC) carries a dismal prognosis, urging the discovery of novel therapeutic targets. Here, we investigate the uncharacterized protein PPP1R18 as a potential driver of ccRCC malignancy.
methodsPPP1R18 expression and its prognostic value were evaluated using TCGA, GEO, and CPTAC databases, with validation in clinical samples and cell lines. The biological functions of PPP1R18 were assessed in vitro using siRNA-mediated knockdown in a series of in vitro assays and an in vivo xenograft model. The underlying molecular mechanisms were explored through bioinformatic analysis, Western blotting, and rescue experiments using specific pathway agonists and inhibitors to delineate the signaling cascade.
resultsPPP1R18 is significantly upregulated in ccRCC and serves as a robust independent predictor of poor survival. Knockdown of PPP1R18 substantially impaired ccRCC cell proliferation, migration, and invasion in vitro and suppressed tumor growth in vivo. Mechanistically, PPP1R18 depletion suppressed the phosphorylation of ERK and inhibited the Wnt/β-catenin pathway, leading to a reversal of the epithelial-mesenchymal transition (EMT) phenotype. Notably, activation of the ERK pathway rescued the inhibitory effects of PPP1R18 knockdown on Wnt/β-catenin signaling and malignant phenotypes. This rescue was subsequently abrogated by a Wnt/β-catenin inhibitor, confirming that Wnt/β-catenin acts downstream of the PPP1R18/ERK axis.
conclusionPPP1R18 is a crucial oncogenic driver and prognostic biomarker in ccRCC. It promotes malignant phenotypes by activating the novel ERK/Wnt/β-catenin signaling axis, offering a potential new target for ccRCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.